An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
The sudden death of a young athlete always prompts full media attention, most recently spurring a call for preventative screening methods, including costly electrocardiogram tests for all school-age athletes.
Two new retrospective subanalyses of the RE-LY trial, involving Pradaxa capsules, suggested that the reduction in stroke risk achieved with PRADAXA 150mg over warfarin occurred irrespective of CHA2DS2-VASc risk score and the type of non-valvular atrial fibrillation.
Abiomed, Inc., a leading provider of breakthrough heart support technologies, today announced the final results from the PROTECT II study, presented by William O'Neill, M.D., Dean of University of Miami and Principal Investigator of PROTECT II, at the American College of Cardiology's 60th Annual Scientific Session and i2 Summit 2011 in New Orleans.
Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.
A study of nearly 600 patients with severe non-inflammatory respiratory disease has found that a significant percentage also suffered from anaemia, according to the April issue of IJCP, the International Journal of Clinical Practice.
Cardiac experts who fix arrhythmias, which are electrical problems of the heart, must perform complex catheter procedures while the heart is still beating in order to pinpoint where an electrical malfunction is taking place.
BIOTRONIK SE & Co. KG, a leading manufacturer of cardiac devices, announced today that the last chronic heart failure patient was enrolled in IN-TIME at the Schwabing Clinic in Munich, Germany, with principle investigator Professor Stefan Sack, MD.
The Canadian Cardiovascular Society and Canadian Heart Rhythm Society have produced the first-ever comprehensive guidelines on the use of genetic testing in the clinical management of inherited heart rhythm disorders, released in the March/April issue of the Canadian Journal of Cardiology published by Elsevier.
Reducing cardiovascular risk factors like high blood pressure, smoking, diabetes and being overweight could potentially reduce more than half of all cases of atrial fibrillation, according to research reported in Circulation: Journal of the American Heart Association.
Medtronic, Inc. today announced U.S. Food and Drug Administration approval of the Protecta portfolio of implantable cardioverter-defibrillators and cardiac resynchronization therapy-defibrillators.
Medtronic, Inc. today announced that the U.S. Food & Drug Administration has approved its Consulta and Syncra cardiac resynchronization therapy-pacemaker systems.
Lee Ryan, 74, a Worth, Illinois man was among the first in Chicago to receive a MRI-compatible pacemaker. His pacemaker was implanted at MetroSouth Medical Center, a hospital known for its excellent cardiac care.
A new health economic analysis, published today online in Thrombosis and Haemostasis, suggested that Boehringer Ingelheim's novel oral direct thrombin inhibitor, dabigatran etexilate, is cost-effective compared to current treatment options, particularly in "real-world" clinical practice.
St. Jude Medical, Inc., a global medical device company, today celebrated the grand opening of the St. Jude Medical Advanced Technology Center Asia Pacific, located in Beijing, China.
Sports medicine physician Steve Watts says cardiac screening for young athletes is useful in preventing sudden cardiac death and suggests new diagnostics have the potential to add value and change the debate about the viability of cardiac screening for young athletes in the United States.
Advanced Cardiac Therapeutics, Inc., a developer of innovative temperature-sensing cardiac ablation systems, today announced that the first patients have been enrolled in a first-in-man CE Mark clinical trial of the safety and performance of the company's TEMPASURE™ cardiac ablation catheter. The TEMPASURE system is the world's first RF cardiac ablation catheter to offer both saline irrigation and temperature-sensing technology.
Did you know that heart attacks can give you mathematics? That statement appears on the web site of James Keener, who works in the mathematics of cardiology. This area has many problems that are ripe for unified attack by mathematicians, clinicians, and biomedical engineers.
The Mount Sinai Medical Center has become the first hospital in the United States to perform a cardiac catheterization procedure using the TactiCath force-sensing ablation catheter for the treatment of symptomatic paroxysmal atrial fibrillation, or periodic rapid and irregular heartbeats.
Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.
The first laboratory-based researchers have moved into the University of Michigan's North Campus Research Complex (NCRC), bringing with them cutting-edge research that uses stem cells to create new heart muscle and focuses on the crucial squeezing action of the heart.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.